Thursday
March 20, 2025
8:00 AM ET
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Thursday
March 13, 2025
7:30 AM ET
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Wednesday
January 8, 2025
8:00 AM ET
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Tuesday
November 12, 2024
8:00 AM ET
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Monday
November 11, 2024
8:00 AM ET
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Thursday
November 7, 2024
8:00 AM ET
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Wednesday
October 23, 2024
8:00 AM ET
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
Tuesday
October 22, 2024
8:00 AM ET
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations